CVM - CEL-SCI Corp Stock Price, Fair Value and News

$0.95+0.05 (+5.56%)

Delayed as of 22 Oct 2024, 10:00 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CVM Price Action

Last 7 days

-10%

Last 30 days

-16.7%

Last 90 days

-37.5%

Trailing 12 Months

-15.9%

CVM RSI Chart

CVM Valuation

Market Cap

55.3M

Price/Earnings (Trailing)

-1.95

Price/Sales (Trailing)

154.15

EV/EBITDA

-2.36

Price/Free Cashflow

-2.9

CVM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CVM Fundamentals

CVM Revenue

Revenue (TTM)

462.8K

CVM Earnings

Earnings (TTM)

-28.4M

Earnings Growth (Yr)

18.06%

Earnings Growth (Qtr)

5.36%

CVM Profitability

EBT Margin

-7536.20%

Return on Equity

-335.67%

Return on Assets

-118.17%

Free Cashflow Yield

-34.54%

CVM Investor Care

Shares Dilution (1Y)

30.12%

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2019	469.7K	466.2K	462.8K	0
2018	0	0	476.6K	473.1K
2017	207.5K	342.0K	0	0
2016	98.0K	85.5K	73.0K	0
2015	116.9K	112.5K	110.5K	0
2014	120.0K	121.4K	122.9K	120.2K
2013	116.6K	116.8K	117.1K	118.5K
2012	536.1K	326.1K	116.1K	116.3K
2011	554.7K	755.4K	956.2K	746.1K
2010	0	116.7K	153.3K	354.0K
2009	0	0	80.1K	0

Get all data in R, Python etc through our Historical Stock Data APIs

About CEL-SCI Corp

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

WEBSITE	https://cel-sci.com
SECTOR	Healthcare
INDUSTRY	Biotechnology

CEL-SCI Corp Frequently Asked Questions

What is the ticker symbol for CEL-SCI Corp? What does CVM stand for in stocks?

CVM is the stock ticker symbol of CEL-SCI Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CEL-SCI Corp (CVM)?

As of Mon Oct 21 2024, market cap of CEL-SCI Corp is 55.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CVM stock?

You can check CVM's fair value in chart for subscribers.

Is CEL-SCI Corp a good stock to buy?

The fair value guage provides a quick view whether CVM is over valued or under valued. Whether CEL-SCI Corp is cheap or expensive depends on the assumptions which impact CEL-SCI Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CVM.

What is CEL-SCI Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Oct 21 2024, CVM's PE ratio (Price to Earnings) is -1.95 and Price to Sales (PS) ratio is 154.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CVM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on CEL-SCI Corp's stock?

In the past 10 years, CEL-SCI Corp has provided -0.252 (multiply by 100 for percentage) rate of return.